Capsugel Could Land In Private Equity Crosshairs If Pfizer Divests
This article was originally published in The Tan Sheet
Executive Summary
Capsugel likely will be the first divestiture from Pfizer's Diversified Businesses following the 2009 Wyeth merger and reorganization, and could be a prime target for a private equity acquisition
You may also be interested in...
Pfizer's OTC, Nutritional Businesses Could Be Looking For A New Home
Pfizer's consumer and nutritional businesses soon may be for sale, but the timing may not be right for the most likely buyers, market analysts say.
Pfizer's OTC, Nutritional Businesses Could Be Looking For A New Home
Pfizer's consumer and nutritional businesses soon may be for sale, but the timing may not be right for the most likely buyers, market analysts say.
Pfizer's OTC, Nutritional Businesses Could Be Looking For A New Home
Pfizer's consumer and nutritional businesses soon may be for sale, but the timing may not be right for the most likely buyers, market analysts say.